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Abstract 
Background Age-related macular degeneration (AMD) is a common sight threatening 
condition.  However, there are a number of monogenic macular dystrophies that are clinically 
similar to AMD, which can potentially provide pathogenetic insights. 
Methods Three siblings from a non-consanguineous Greek-Cypriot family reported central 
visual disturbance and nyctalopia. The patients had full ophthalmic examinations and color 
fundus photography, spectral- domain ocular coherence tomography and scanning laser 
ophthalmoscopy. Targeted polymerase chain reaction (PCR) was performed as first step to 
attempt to identify suspected mutations in C1QTNF5 and TIMP3 followed by whole genome 
sequencing. 
Results The three patients were noted to have symptoms of nyctalopia, early paracentral 
visual field loss and, in older patients, central vision loss. Imaging identified pseudodrusen, 
retinal atrophy and RPE-Bruch’s membrane separation. Whole genome sequencing of the 
proband revealed two novel heterozygous variants in C1QTNF5, c.556C>T and c.569C>G. 
The mutation segregated with disease in this family, occurred in cis, and resulted in missense 
amino acid changes P186S and S190W in C1QTNF5. In silico modelling of the variants 
revealed that the S190W mutations was likely to have the greatest pathologic effect and that 
the combination of the mutations was likely to have an additive effect. 
Conclusions The novel mutations in C1QTNF5 identified here expand the genotypic 
spectrum of mutations causing late-onset retinal dystrophy.  
 
Keywords: Macular dystrophy, nyctalopia, whole genome sequencing, C1QTNF5,  
  
WHOLE GENOME SEQUENCING REVEALS NOVEL MUTATIONS CAUSING 
AUTOSOMAL DOMINANT INHERITED MACULAR DEGENERATION 
 
Introduction 
Age-related macular degeneration (AMD) is one of the commonest causes of blindness in the 
developed world (1).  Early AMD is identified clinically by focal sub-retinal deposits known 
as drusen (2).  Late stage disease results in two main forms of disease; neovascular or wet  
AMD which results from choroidal neovascularization and dry or non-neovascular AMD 
which results in an insidious loss of the retinal pigment epithelium (RPE) followed by neuro-
retinal atrophy leading to geographic atrophy. Non-nvAMD is the commonest form of AMD 
accounting for up to 90% of cases (3).   
There are a number of Mendelian inherited diseases which mimic AMD with the 
development of drusen or drusen-like sub-RPE deposits, pseudodrusen, retinal atrophy and 
choroidal neovascularization (CNV). These diseases include late-onset retinal dystrophy (L-
ORD), Sorsby fundus dystrophy (SFD) and dominant drusen/Doyne’s honeycomb macular 
dystrophy (DD) for which a number of mutations have previously been described (4-6).  
In this article we describe the investigation of members of a family who present with macular 
degeneration with an autosomal dominant inheritance pattern. Standard screening of known 
mutation loci was negative for disease in this family. 
Materials and Methods 
Three patients from a single family were examined in the clinics of Moorfields eye hospital 
(MEH), London. All subjects underwent an ophthalmic examination performed by an 
ophthalmologist, which included best-corrected Snellen visual acuity (BCVA), slit lamp 
biomicroscopy of the anterior segment, and dilated fundus examination. Color fundus 
photographs were obtained (Topcon 3D OCT, Topcon Corporation, Tokyo, Japan).  Fundus 
autofluorescence (FAF) imaging was performed using 30° or 55° lenses using a confocal 
scanning laser ophthalmoscope (HRA+OCT Spectralis, Heidelberg Engineering, Heidelberg, 
Germany) and spectral-domain optical coherence tomography (SD-OCT) (HRA+OCT 
Spectralis, Heidelberg Engineering, Heidelberg, Germany) were performed on all patients. 
Additional pseudo color and ultra-widefield confocal scanning laser (Optos plc, Dunfermline, 
UK) were performed on some patients. Full-field electroretinography (ffERG) and pattern 
ERG (PERG) were also performed according to the standards agreed by the International 
Society for Clinical Electrophysiology of Vision Standards on one of the patients (7, 
8). Patients were dark adapted for a minimum of 20 minutes. The ffERGs were recorded 
under dark-adapted conditions to flash strengths of 0.01 and 10.0 candelas/s/m−2 (cd/s/m−2) 
and light-adapted ffERGs to a flash strength of 3.0 cd/s/m−2 (30 Hz and 2 Hz).  Informed 
written consent and peripheral blood samples were obtained for genetic analysis from all 
participants according to the protocols approved by the Research Management Committees of 
Moorfields Eye Hospital and in agreement with the tenets of the declaration of Helsinki. 
For initial molecular investigations in the proband a PCR amplification was performed to 
amplify intron 4 and exon 5 of TIMP3 and the c.489 C>G mutation region in C1QTNF5. The 
amplicons were sequenced using standardized sequencing protocols. Whole genome 
sequencing was performed as part of the National Institute for Health Research (NIHR) 
BioResource- Rare Diseases study and was performed as previously described (9). Briefly, 
WGS used the Illumina TruSeq DNA PCR-Free Sample preparation kit (Illumina, Inc.) and 
sequenced using an Illumina HiSeq 2500, generating minimum coverage of 15× for 
approximately 95% of the genome. Reads were aligned to the Genome Reference Consortium 
human genome build 37 (GRCh37) using Isaac Genome Alignment Software (version 01.14; 
Illumina, Inc.). Single nucleotide variations and small insertion deletions were identified 
using Isaac Variant Caller (version 2.0.17). To facilitate variant interpretation, a list of 
reported IRD-associated genes was assembled, including genes associated with syndromic 
forms of IRD or albinism, from various sources including RetNet and literature searches. 
This list was manually curated according to published evidence of pathogenicity to compile a 
shortlist of 224 high-confidence IRD associated genes. To identify pathogenic variants, a 
two-step variant filtering protocol was designed, utilizing automated filtering followed by 
manual review. For SNVs and indels, automated filtering identified variants that fulfil the 
following criteria: passes standard Illumina quality filters in >80% of the whole NIHR 
BioResource Rare Diseases cohort (n. 6,688); predicted to be a high impact, medium impact, 
or splice region variant, or present in the HGMD Pro database; 22 and has minor allele 
frequency (MAF) < 0.01 in control datasets including the NIHR BioResource Rare Diseases 
cohort and the Exome Aggregation Consortium (ExAC) database. If a variant is present in the 
HGMD Pro database, a higher MAF threshold of 0.1 was used. Finally, we identified just 
those variants that affect an IRD-associated gene.  Confirmatory bidirectional Sanger 
sequencing of C1QTNF5 was performed in all available family members. Amplification of 
DNA was performed using specifically designed primers by polymerase chain reaction, and 
the resulting fragments were sequenced using standard protocols. 
Variant nomenclature was assigned in accordance with GenBank Accession 
number NM_015645.4, with nucleotide position 1 corresponding to the A of the ATG 
initiation codon. Variants were identified as novel if not previously reported in the literature 
and if absent from dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/), EVS, and the 
Exome Aggregation Consortium database (ExAC; http://exac.broadinstitute.org) containing 
61 486 exomes, all accessed on 25/3/2016. Where relevant, potential splice site disruption 
was assessed using Splice Site Prediction by Neural Network 
(http://www.fruitfly.org/seq_tools/splice.html). 
UCSC genome browser was used to check for orthologues and conservation of protein 
sequence amongst species. Pathogenicity of the novel variant and original mutations were 
assessed using predictive algorithms of “Sorting Intolerant From Tolerant” (SIFT; in the 
public domain, http://sift.jcvi.org), Polymorphism Phenotyping v2 (PolyPhen-2; in the public 
domain, http://genetics.bwh.harvard.edu/pph2) and Mutationtaster 
(http://www.mutationtaster.org/). 
The effects of each amino acid substitution on protein folding and assembly were predicted 
with the FoldX package, using the homotrimeric crystal structure of the human C1QTNF5 
gC1q domain (PDB ID: 4NN0). A model of the 18-mer assembly was constructed based 
upon contacts present in the asymmetric unit of this structure. The predicted effect upon on 
protein folding was calculated using from the FoldX-calculated change in stability induced by 
an amino acid substitution for the isolated monomeric subunit. The predicted effect on trimer 
assembly was calculated as the difference between the change in stability for the trimer and 
the monomeric subunit in isolation. Finally, the predicted effect on higher-order assembly 
was calculated as the difference between the change in stability for the 18-mer and the trimer. 
When considering the trimer and 18-mer complexes, only a single subunit was mutated, 
reflecting the heterozygous nature of the mutations. The FoldX “RepairPDB” function was 
run prior to mutations. Ten FoldX replicates were performed for each mutation, and the 
average was presented here. 
 
Results 
A three generation non-consanguineous Greek Cypriot family with macular degeneration was 
studied. Inheritance followed an autosomal dominant pattern (Fig 1A).  The proband (II:4) 
was initially seen in 2011 aged 65. He was already registered blind and was otherwise well 
except for cardiovascular disease for which he had been treated with a stent 4 years 
previously. He continued to take aspirin, atenolol, clopidogrel, simvastatin and famotidine. 
He was asymptomatic until his sixth decade. Aged 54 years he presented with difficulty with 
night time vision, driving and reading. By the time of examination at MEH his BCVA was 
hand movements bilaterally. Slit lamp examination revealed posterior chamber intra-ocular 
lenses bilaterally (Fig 2A).  Fundus examination identified widespread retinal atrophy in the 
macula within the arcades with further peripheral scalloped atrophy (Fig 2B and C).  SD-
OCT with a cross section at the fovea revealed marked central retinal thinning suggesting 
neuroretinal atrophy at the fovea, sub-RPE deposits temporally and a thinned choroid (Fig 2D 
and E). Visual field to confrontation was diminished. Known mutations for L-ORD and SFD 
were excluded by PCR based sequencing. 
The sister of the proband (II:3) was first seen aged 67.  She had experienced 4 years of night 
blindness with worsening of central vision in both eyes and had a previous medical history of 
treated hypertension, asthma and ischemic heart disease. Examination revealed a BCVA of 
6/12 bilaterally.  Anterior segment examination revealed mild cataracts with only a few long 
anterior zonules superiorly which were difficult to identify on photography but were more 
clearly seen on examination (Fig 3A).  Fundus examination at first presentation showed 
marked atrophy at the macula with foveal sparing (Fig 3B) and more scalloped atrophy to the 
mid-periphery which were clear on SLO (Fig 3C). SD-OCT revealed near uniform sub-retinal 
thickening across the fundus (Figs 3D, 3E). Goldmann visual field (supplementary figure 1) 
were markedly reduced using III4e target and after 5 years of review there was marked 
progression of macular changes (Fig 3D). The phenotype resembled late-onset retinal 
dystrophy (L-ORD) which is an autosomal dominant retinal dystrophy usually presenting 
with dark adaptation delay and later central visual loss and which demonstrates marked 
macular, retinal atrophy and sub-RPE thickening on SD-OCT. However, testing for the c.489 
C>G, p.S163R mutation for L-ORD did not identify any pathogenic change.  
Case (II:7) was first seen in 2014 aged 54. She complained of mild dark adaptation delay. She 
was myopic with a previous history of right anisometropic amblyopia. She was otherwise 
healthy except for a history of hypertension controlled with losartan. Her BCVA was 6/18 
right and 6/5 left. Examination revealed fine long anterior zonule fibers superiorly at the lens 
(Fig 4A). Fundus examination revealed small white lesions outside the arcades with atrophy 
temporal to the macula (Fig 4B). There was bilateral peripapillary atrophy greater on the right 
than the left eye. Occasional pigment clumps were seen. The SD-OCT revealed areas of sub-
retinal thickening.  This was again in the temporal peripheral macula consistent with other L-
ORD cases and this region was also the first to have reduced auto-fluorescence (Figs 4C, D 
and E).  Ishihara color vision testing was full. Humphrey visual field testing identified 
increased blind spots on the right greater than the left (supplementary figure 2). 
Electroretinography showed mild generalized loss of rod function with no cone system 
involvement.  
The absence of causative mutations at the suspected loci for SFD and L-ORD prompted 
investigation using whole genome sequencing.  The proband was found to have two 
heterozygous variants at c.556C>T (p.P186S) and c.569C>G (p.S190W) in C1QTNF5 
(chromosome 11 position 119210217 and 119210204 respectively). These appeared to be in 
cis from inspection of the WGS reads (supplementary figure 4) in which the variants were 
always on the same read, when spanning both loci. These were confirmed by bidirectional 
sequencing of the PCR product of primers flanking this region (Fig 1B), and were shown to 
segregate with the disorder in two further affected and 3 unaffected siblings (likelihood given 
no linkage = 1:32, p= 0.03, LOD score = 1.5) 
To see if the two variants were novel we reviewed the ExAC database. The amino acids are 
highly evolutionarily conserved across species (supplementary figure 3). To confirm that the 
variants were pathogenic we used several online prediction tools to assess the impact of the 
amino acid substitutions (Fig 5B). The amino acid substitution S190W was found to be more 
consistently damaging than the P186S. The findings also compare favorably when compared 
to the prototypic S163R mutation suggesting that the variants are pathogenic. 
To understand how the variants may potentially affect trimerization and multimers formation 
we performed in silico mutagenesis as previously described. (10)Computational modelling 
indicated that the S190W substitution had a highly destabilizing effect upon trimer assembly, 
resulting in a calculated free energy difference (ΔΔG) of 9.7 kcal/mol, compared to the  
wild-type protein (Fig 5B). When combined with P186S, there was an additive effect of 
both the mutations, with a total ΔΔG of 12.3 kcal/mol. This is as highly destabilizing as 
the known pathogenic variants S163R and G216C reported previously.(10) To identify if a 
potential mechanism for pathogenicity we generated a three dimensional model of 
monomeric and multimeric C1QTNF5. The novel variants P186S and S190W cluster near to 
previously identified pathogenic mutations on the surface of the globular domain of 
C1QTNF5 suggesting that this is an important region for C1QTNF5 multimerisation. 
Discussion 
This report describes three cases from a pedigree who present with macular dystrophy with 
an autosomal dominant inheritance pattern. Although the cases tested negative for the 
prototype S163R mutation in C1QTNF5 which results in L-ORD, their clinical presentation 
was mainly consistent with L-ORD (11-17) as outlined by a previously described staging 
system (18). In this simple three stages system, stage 1 (0-40 years of age) patients were 
asymptomatic but may demonstrate long anterior zonules (LAZ). In stage 2 (40-60 years of 
age), patients report dark adaptation delay and nyctalopia and are noted to have macular 
degeneration sparing the fovea and clinical dark adaptometry delay.  In stage 3 (>60 years of 
age), patients lose central vision progressively and by late stage 3 disease there is full visual 
field loss.  The clinical findings of L-ORD have been summarized by a number of studies 
(11-17). 
There were a number of differences in the affected patients when compared to cases 
harboring the classical S163R mutations. The LAZ normally demonstrate peripupillary trans-
illumination defects however these were absent in all our cases. Additionally, the proband 
(II:4) already had bilateral cataract surgery which would have precluded the identification of 
long anterior zonules (Fig 2A). There was some variability in the presentation of visual 
symptoms amongst the cases. All three patients admitted to having symptoms of dark 
adaptation delay. However, proband (II:4) and (II:7) described symptoms from the age of 54.  
However, case (II:3) appears to have milder disease with symptoms starting in her early 
seventh decade.  Similarly case (II:3) has conserved central vision whilst proband (II:4) who 
is younger has already lost central vision bilaterally.  
L-ORD is a fully penetrant autosomal dominant macular and retinal degeneration. The first 
identified mutation in C1QTNF5 resulted from a substitution (S163R) (L-ORD,   OMIM   
608752).  However, recently several additional pathogenic variants in C1QTNF5 have been 
identified (10). Patients with L-ORD develop early drusenoid deposits, thick sub-RPE 
deposits which extend to the ora serrata, RPE atrophy and later widespread geographic 
atrophy (15). L-ORD results from a mutation in the gene C1QTNF5 (6).  The gene encodes a 
protein of the same name which is expressed by the RPE and ciliary body within the eye and 
is composed of a globular domain and collagen like domain with a nitrile end (19).  The 
protein belongs to the C1Q tumor necrosis superfamily which includes adiponectin (20). 
C1QTNF5 has been shown to have metabolic function increasing AMPK phosphorylation 
(21).   
C1QTNF5 is composed of 3 exons.  Exon 1 is a non-coding exon.  Exon 2 contains the start 
codon for translation codes for the N-terminal signal peptide and the collagen-like domain 
and exon 3 codes for the C-terminal globular domain (22).  Translation results in a 25kDa 
monomeric protein. C1QTNF5 forms trimers and has been shown to form high order 
multimers (6, 14, 19).  The proposed novel pathogenic variants in this pedigree are located at 
c.556C>T (P186S) and c.569C>G (S190W) in C1QTNF5.  
The exact effect of the mutations on C1QTNF5 protein are yet to be established. The crystal 
structure of full length C1QTNF5 was demonstrated by Tu and Palczewski (19). C1QTNF5 
has a complex structure leading to the formation of high order multimers resulting from 
complex hydrophobic and hydrophilic interactions, hydrogen bonds and disulfide bonds (19, 
23). The globular domain, where the mutations are all located, appears important for 
trimerization of C1QTNF5. The globular heads of C1QTNF5 contain 10 strands arranged in 
two anti-parallel β-sheets (24). The β-sheets are brought together by a hydrophobic ‘zipper’ 
(19).  
The pathogenic variants identified in this study as well as the previously identified variants 
all encode amino acids found on the surface of the globular domain of C1QTNF5 (Fig 5A) 
and form part of an apical loop which is predicted to play an important role in the interaction 
between C1QTNF5 monomers (19).  As a result it is predicted that they may disrupt 
trimerization. Using in silico modelling and energy stability calculations both novel variants 
were found to destabilize C1QTNF5 folding.  A combination of both variants may result in a 
greater pathogenic impact on C1QTNF5 stability. A review of the GNOMAD database 
reveals that there are loss of function variants in C1QTNF5, which do not result in eye 
disease suggesting that the changes are not likely to be due haplodeficiency. Therefore, the 
two variants are likely to be dominant negative or neomorphic alleles if they are pathogenic. 
As the mutations were found in cis it was not thought predicted that disease severity would be 
altered by the two mutations with a dominant-negative mechanism proposed.  The onset and 
progression of the case phenotypes was within the normal range of expected phenotypes for 
L-ORD. 
Recent studies using a human RPE expressing the recently identified mutations appear to 
confirm in silico predictions. There was a change in the polarity of C1QTNF5 secretion from 
the apical to basal membranes of RPE.  This may contribute to the thick deposits seen in post-
mortem samples of human L-ORD eyes and in the BM-RPE separation noted in the retinal 
SD-OCT scans of our patients (10, 15, 17, 25). We propose a similar disease mechanism for 
the novel pathogenic variants identified in our patients.  
A problem has been the validation of candidate pathogenic variants.  Whilst functional 
studies have so far proved the gold standard for validation it is currently too time consuming 
and costly to provide a functional characterization of all newly discovered candidate 
pathogenic variants.  A set of online tools has proven useful to confirm pathogenicity as has 
been used in this study. We also describe the use of computer modelling to identify protein 
stability.   Analysis comparing the accuracy of modelling tools compared to functional and 
experimental studies has shown that although they are accurate in identifying energy stability 
changes, they underestimate the ΔΔG (26). However, modelling tools may be particularly 
useful to test in the setting of genes coding for proteins involved in complex or high order 
structures such as C1QTNF5 where generation of complexes or high order hetero-multimers 
may be difficult in vitro.  Tools which combine various predictions including computer 
modelling such as meta-predictors are increasingly being developed using machine learning 
and may prove even more accurate in prediction in the future (27). 
In summary, we describe the clinical and molecular findings of a family presenting with a 
dominant macular degeneration.  We identified novel pathogenic variants in the gene 
C1QTNF5 which resulted in the clinical findings of nyctalopia, thick sub–RPE deposits, 
pseudodrusen, RPE and neuro-retinal atrophy.  The condition shares clinical similarities with 
the autosomal dominant macular degeneration L-ORD. 
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Figure 1 Family pedigree and electropherograms for the affected family. (A) Inheritance 
followed an autosomal dominant inheritance pattern. Base pair status was confirmed at 
suspected mutation sites for individuals tested within the family. (B and C) 
Electropherograms depicting patient wild- type and mutation sequences from the sense strand 
of genomic DNA. (B) An unaffected sibling shows wild type sequence at the suspected 
mutation sites (yellow band) (C) The proband demonstrates substitutions c.556C>T 
(p.P186S) and c.569C>G (p.S190W) at the suspected sites (yellow band).  
 
Figure 2 Imaging of proband (II:4).  (A) Anterior segment photograph showing 
capsulorhexis and intra-ocular lens with no clear lens zonules. (B) Ultra-widefield 
pseudocolor images showing marked retinal atrophy involving the fovea and peripheral 
macula. (C) Ultra-widefield SLO showing marked scalloped areas of reduced 
autofluorescence surrounded by a ring of increased autofluorescence. (D) Infra-red line scan. 
(E) SD-OCT line scan through the fovea showing neuro-retinal atrophy and sub-retinal 
deposits (white arrows) above Bruch’s membrane.  Additionally there is a markedly 
atrophied choroid.  
 
Figure 3 Imaging of case (II:3).  (A) Anterior segment photograph showing sparse superior 
fine long anterior zonules (white arrows). (B) Color fundus photograph at initial presentation 
showing large islands of atrophy across the macula and beyond the vascular arcades but 
sparing the fovea. (C) SLO showing islands of reduced autofluorescence sparing the fovea at 
first presentation. (D) 5 years follow-up SLO showing increasing areas of reduced 
autofluorescence involving the fovea. (E) Infra-red line scan (F) SD-OCT line scan 
performed at first presentation through the fovea showing mild neuro-retinal atrophy with 
loss of the ellipsoid and ELM hyper-reflective lines except for the fovea and sub-retinal 
deposits (red arrows) above Bruch’s membrane (Inset).  Additionally there is a markedly 
atrophied choroid.  
 
Figure 4 Imaging of case (II:7).  (A) Anterior segment photograph showing fine long anterior 
zonules superiorly and inferiorly. (B) Ultra-widefield pseudocolor images show mild 
peripapillary atrophy.  Additionally there are pigmentary and atrophic changes in the 
temporal macula (C) Ultra-widefield SLO showing early scalloped areas of reduced 
autofluorescence surrounded by a ring of increased autofluorescence in the temporal macula. 
(D) Infra-red line scan. (E) SD-OCT line scan through the fovea showing loss of the ellipsoid 
and external limiting membrane in the temporal fovea with a sub-retinal deposit in the same 
region (red arrows).  
 
Figure 5 C1QTNF5 protein structure model and stability prediction. (A) Transverse view of 
the three dimensional structure of trimeric C1QTNF5 with the positions of the previously 
described mutations (red) and novel mutations highlighted (purple). (B) Energy stability of 
the previous mutations and the new mutations as well as the combination of the two new 
variants in C1QTNF5 in monomer, trimer and high order. 
 
 
 
 
 
